FLXN

0.22% -15.91

시간 외 거래: 25.05 -0.000100 -0.00%

Flexion Therapeutics, Inc. (FLXN)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Flexion Therapeutics, Inc. Stock (FLXN) Company Profile

Flexion Therapeutics, Inc.

Healthcare (1102)

781-305-7777

10 Mall Road, Suite 301, Burlington

최신 SEC 제출 서류

FLXN's Discussions on Twitter

Compare FLXN vs TAK, HLN, TEVA, ZTS, UTHR

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
FLXN Flexion Therapeutics, Inc.	25.05	0	0	0	0	0.00
TAK Takeda Pharmaceutical Co Adr	15.84	49.39B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	8.95	39.55B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.21	36.66B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	76.84	33.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	544.33	22.78B	3.17B	1.29B	1.01B	27.09

Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-04-26	재개	Credit Suisse	Outperform
2021-04-07	재개	RBC Capital Mkts	Outperform
2020-08-20	개시	Goldman	Neutral
2020-07-31	개시	Oppenheimer	Outperform
2020-07-29	개시	Credit Suisse	Outperform
2020-06-25	개시	H.C. Wainwright	Buy
2020-05-27	개시	Guggenheim	Buy
2019-12-27	재확인	The Benchmark Company	Buy
2019-12-05	개시	Craig Hallum	Buy
2019-11-25	개시	BTIG Research	Buy
2019-05-09	업그레이드	The Benchmark Company	Hold → Buy
2019-01-04	재확인	Needham	Buy
2019-01-04	다운그레이드	The Benchmark Company	Buy → Hold
2018-06-28	개시	The Benchmark Company	Buy
2017-10-09	재확인	Needham	Buy
2017-08-24	개시	Northland Capital	Outperform
2016-12-22	개시	Raymond James	Strong Buy
2016-09-06	재개	Lake Street	Buy
2016-07-21	개시	Lake Street	Buy
2016-05-03	재개	Wells Fargo	Outperform
2015-11-04	개시	Cantor Fitzgerald	Buy
2015-09-09	재확인	Needham	Buy

Flexion Therapeutics, Inc. 주식(FLXN)의 최신 뉴스

Flexion Therapeutics, Inc. (FLXN) 재무 분석

Flexion Therapeutics, Inc. (FLXN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Flexion Therapeutics, Inc. (FLXN)

Flexion Therapeutics, Inc. Stock (FLXN) Company Profile

Compare FLXN vs TAK, HLN, TEVA, ZTS, UTHR

Flexion Therapeutics, Inc. Stock (FLXN) Upgrades & Downgrades

Flexion Therapeutics, Inc. 주식(FLXN)의 최신 뉴스

Osteoarthritis Therapeutics Market Size & Share | Forecast Report 2035 - Research Nester

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - The Manila Times

Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com Australia

Tempest Therapeutics appoints two directors to board - Investing.com UK

Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan

Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart.com

FLXN Stock Price, Quote & Chart | HORIZON FLEXIBLE INCOME ETF (NYSEARCA:FLXN) - ChartMill

Top Players and Competitive Dynamics in the Osteoarthritis Therapeutics Market - openPR.com

Knee Osteoarthritis Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com

Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com

Versant Side Fund III L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga

Analysis of Key Market Segments Driving the Joint Pain Injections Market - openPR.com

Flexion Therapeutics, Inc.Common Stock (NY: FLXN - The Chronicle-Journal

Akin Advises Pharmakon in $100 Million Debt Financing for Paratek Pharmaceuticals and Radius Health Combination - Akin

Paratek Pharmaceuticals to Combine with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform - Sixth Street

Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals

Intra-Articular Injections Market Size to Hit USD 13.65 Billion by 2035 - Precedence Research

Joint Pain Injections Market Overview and Leading Players: - openPR.com

PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz

Meredith Marlin Appointed as SVP, Total Rewards at Regeneron - hrtoday.in

Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® (... - ADVFN

Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates - ADVFN

Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® (triamcinolone acetonide extended-release... - ADVFN

Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (... - ADVFN

Osteoarthritis Therapeutics Market Size to Hit USD 26.31 billion by 2035 - Precedence Research

Anti-Inflammatory Therapeutics Market Size to Hit USD 164.44 Bn by 2035 - Precedence Research

Knee Osteoarthritis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Globe and Mail

PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - BioSpace

Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight - The Globe and Mail

Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma

Non-Opioid Pain Treatment Market Size, Share | CAGR Of 8.1% - Market.us

Knee Osteoarthritis Treatment Market Size, Share | CAGR Of 7.7% - Market.us

Knee Osteoarthritis Injectable Treatments Market Size to Hit USD 6.78 Billion by 2035 - Precedence Research

Knee Osteoarthritis (OA) Injectable Treatments Market Revenue to Attain USD 5.94 Bn by 2033 - Precedence Research

Flexion Therapeutics (NASDAQ:FLXN) - intelligentinvestor.com.au

Syncromune Appoints Kerri-Ann Millar as Chief Financial Officer - citybiz

Catalyst Pharmaceuticals Appoints Dr. William T. Andrews as Chief Medical Officer | CPRX Stock News - Quiver Quantitative

Anti-Inflammatory Therapeutics Market Size, Value & Trends | By 2033 - Straits Research

Osteoarthritis Therapeutics Market Size [2033] Report - SkyQuest Technology

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire

From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide - Baylor College of Medicine Blog Network -

Gene Therapies For Rare Diseases Market Share, Size, Growth and Forecast to 2031 - Insightace Analytic

Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer - GlobeNewswire

Global Non-Steroidal Anti-Inflammatory Drugs Market is - GlobeNewswire

Osteoarthritis Treatment Market 2032: FDA Approvals, Clinical - openPR.com

Pacira BioSciences Reports Second Quarter 2024 Financial Results - GlobeNewswire

Avalo Therapeutics Appoints Dr. Mittie Doyle as Chief Medical Officer - citybiz

Boston Pharmaceuticals Appoints Dr. Margaret Koziel as Chief Medical Officer - citybiz

Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 | DelveInsight - PR Newswire

Ocular Therapeutix Appoints Steve Meyers as Chief Commercial Officer - citybiz

Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs - GlobeNewswire

Flexion Therapeutics, Inc. (FLXN) 재무 분석

매출

순이익

현금흐름

주당 순 이익

FLXN과 유사한 종목